LAUSR

Diabetic retinopathy (DR) remains the leading cause of blindness in adults with diabetes mellitus. Numerous microRNAs (miRNAs) have been identified to modulate the pathogenesis of DR. The main purpose of this study was to evaluate the potential roles of miR‐455‐5p in high glucose (HG)‐treated retinal pigment epithelial (RPE) cells and underlying mechanisms. Our present investigation discovered that the expression of miR‐455‐5p was apparently downregulated in ARPE‐19 cells stimulated with HG. In addition, forced expression of miR‐455‐5p markedly enhanced cell viability and restrained HG‐induced apoptosis accompanied by decreased BCL2‐associated X protein (Bax)/B‐cell leukemia/lymphoma 2 (Bcl‐2) ratio and expression of apoptotic marker cleaved caspase‐3 during HG challenged. Subsequently, augmentation of miR‐455‐5p remarkably alleviated HG‐triggered oxidative stress injury as reflected by decreased the production of intracellular reactive oxygen species (ROS) and malondialdehyde (MDA) content as well as NADPH oxidase 4 expression, concomitant with enhanced the activities of superoxide dismutase, catalase, and GPX stimulated with HG. Furthermore, enforced expression of miR‐455‐5p effectively ameliorated HG‐stimulated inflammatory response as exemplified by repressing the secretion of inflammatory cytokines interleukin 1β (IL‐1β), IL‐6, and tumour necrosis factor‐α in ARPE‐19 cells challenged by HG. Most importantly, we successfully identified suppressor of cytokine signaling 3 (SOCS3) as a direct target gene of miR‐455‐5p, and miR‐455‐5p negatively regulated the expression of SOCS3. Mechanistically, restoration of SOCS3 abrogated the beneficial effects of miR‐455‐5p on apoptosis, accumulation of ROS, and inflammatory factors production in response to HG. Taken together, these findings demonstrated that miR‐455‐5p relieved HG‐induced damage through repressing apoptosis, oxidant stress, and inflammatory response by targeting SOCS3. The study gives evidence that miR‐455‐5p may serve as a new potential therapeutic agent for DR treatment.